UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

SCHEDULE 14A

(Rule 14a-101)

INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.___)

Filed by the Registrant \boxtimes Filed by a Party other than the Registrant \square

Check the appropriate box: □ Preliminary Proxy Statement

□ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

□ Soliciting Material Pursuant to Sec.240.14a-12

CYCLERION THERAPEUTICS, INC.

(Name of Registrant as Specified in its Charter)

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

 \boxtimes No fee required.

□ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

- (1) Title of each class of securities to which transaction applies:
- (2) Aggregate number of securities to which transaction applies:
- (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
- (4) Proposed maximum aggregate value of transaction:
- (5) Total fee paid:

□ Fee paid previously with preliminary materials.

- □ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration number, or the Form or Schedule and the date of its filing.
 - (1) Amount Previously Paid:
 - (2) Form, Schedule or Registration Statement No.:
 - (3) Filing Party:

(4) Date Filed:



CYCLERION THERAPEUTICS, INC.

2021 Annual Meeting Vote by June 23, 2021 11:59 PM ET



D49911-P51726

You invested in CYCLERION THERAPEUTICS, INC. and it's time to vote!

You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the shareholder meeting to be held on June 24, 2021.

Get informed before you vote

View the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to June 10, 2021. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

| | nation and to vote, trol # | visit www.ProxyVote.com |
|---|----------------------------|---|
| Smartphone users Point your camera here and vote without entering a control number | Virtually a | Vote Virtually at the Meeting* June 24, 2021 8:00 AM, EDT t: Jalshareholdermeeting.com/CYCN2021 |

*Please check the meeting materials for any special requirements for meeting attendance.



CYCLERION THERAPEUTICS, INC. 245 FIRST STREET, RIVERVIEW II, 18TH FLOOR CAMBRIDGE, MA 02142

V1

THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote on these important matters.

| Voting Items | Board Recommends | |
|--|---------------------|--|
| 1. Election of Directors Nominees: 01) Kevin Churchwell, M.D. 06) Stephanie Lovell 02) George Conrades 07) Terrance McGuire 03) Marsha Fanucci 08) Michael Mendelsohn, M.D. 04) Peter M. Hecht, Ph.D. 09) Errol De Souza, Ph.D. 05) Ole Isacson, M.D., Ph.D. | 🕑 For | |
| 2. Ratification of Appointment of Ernst & Young LLP as our Independent Registered Public Accounting Firm. | Ser Sor | |
| NOTE: Such other business as may properly come before the meeting or any adjournment thereof. | | |

Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Sign up for E-delivery".

D49912-P51726